Obsidian Therapeutics, Inc. OBX
Set alert
14.43 USD -0.36 -2.43%
At close
14.00 -0.43 -2.98%
Pre-market · Nov 3, 5:42 AM ET
13.48 Day range 14.92
11.52 52-week range 49.97
- YTD
- -17.54%
- 1 year
- -17.54%
- Open
- 14.62
- Prev close
- 14.79
- Mkt cap
- 891.38M
- Vol
- 526.05K
- Avg vol
- 395.13K
- EPS
- -1.63
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.48
- High
- 14.92
- Forward P/E
- -7.98
- Beta
- 2.60
- Short ratio
- 0.69
- Inst. own
- 27.36%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 31, 2025
- 50-d avg
- 19.99
- 200-d avg
- 19.99
- 1y target
- 39.00
3M chart
Events in this range
- Aug 5, 2026Rating: Piper Sandler · — → Overweight
- Aug 18, 2026Rating: LifeSci Capital · — → Outperform
- Aug 28, 2026Earnings: -1.38; estimate -1.63; surprise 15.34%
- Sep 9, 2026Rating: William Blair · — → Outperform
- Sep 22, 2026Rating: Leerink Partners · — → Outperform
Signals (5)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 27, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 8, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 6, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 24, 2026 | 1 month ago |
Held by funds
13 US ETFs and mutual funds hold OBX · largest positions
Ownership
Held by insiders 0.81%
Held by institutions 27.36%
Float held by institutions 27.58%
Institutions 5
Top institutional holders
No holders on record
Top mutual fund holders
No holders on record
Insiders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHANG NANCY T | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | May 14, 2026 | 0 |
| EMERALD BIOVENTURES LLC | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | May 14, 2026 | 0 |
| FRIEDMAN MICHAEL R | Director | Conversion of Exercise of derivative security | May 14, 2026 | 0 |
| SORENSEN J. MEL | Chief Executive Officer | Sale | Nov 19, 2025 | 195,029 |
| SORENSEN MELINDA | Chief Executive Officer | Sale | Nov 19, 2025 | 195,029 |